Network Insights Methodology Get Access

Novartis

ORG Health Care / Pharmaceuticals Momentum 11.2ML Momentum Score (0-100). Weighted composite of 9 features: mention velocity, article breadth, relationship density, deal context, recency, market cap, enrichment completeness, mention concentration, entity type. CRITICALPSI regime classification. QUIET (<0.3): baseline activity. NORMAL (0.3-0.5): typical deal flow. ELEVATED (0.5-0.7): above-average signals. HIGH (0.7-0.85): significant activity. EXTREME (>0.85): exceptional signal concentration. Primary: Spectral Shift

$96.5B revenue (Basel) manufactures pharmaceuticals, oncology, and specialty medicines across 140 countries. Recent signals indicate US campus expansion and European real estate restructuring as part of strategic footprint optimization.

Domestic US expansion initiatives; real estate optimization including tenant eviction at Slovenian campus; partnership activity with industrial partners on US-based investments.
0.02
PSI ScorePlocamium Signal Index - composite z-score from 5 orthogonal signals: news frequency, targeted sentiment, graph centrality, regulatory filings, and clinical trial activity.
11.2
MomentumML Momentum Score (0-100). Weighted composite of 9 features including mention velocity, article breadth, deal context, and relationship density. Retrained weekly.
1%
ConfidenceSignal confidence - percentage of PSI sub-signals with sufficient data (30+ observations). Higher confidence means the PSI score is based on more complete data.
8
ConnectionsDegree centrality - number of unique entities this entity co-occurs with in news signals and articles. Higher = more connected in the intelligence network.
Novartis is getting less coverage than expected — the market may be ignoring a developing story (primary driver: Attention Cascade).
Connected Entities
Merck Pfizer United States European Union Anthropic Texas China Senator DOD CEO AstraZeneca Airbus Asia Barclays Ohio
Watch This Entity
PSI Intelligence
30-Day Trend
2026-04-25 2026-05-25 10 0 Degree Mentions
Signal Decomposition
Attention Cascade
0.236
Narrative Drift
0.000
Spectral Shift
624.046
Sentiment-Momentum Divergence
0.000
Source Concentration
0.908
Signal
Novartis is getting less coverage than expected — the market may be ignoring a developing story (primary driver: Attention Cascade).
Driver
Ranked #6 of 6 in Health Care — in line with sector peers. PSI stable vs yesterday (-1.00). Confidence: 63% (entity has limited history, score is shrunk toward sector prior).
Action
Baseline conditions. Continue standard monitoring cadence.
Peer Comparison
6 of 6
Sector Rank
+0.00
Peer Z-Score
0%
Sector Percentile
Network Analysis
8 Degree Centrality
Ego Network (top connections)
Merck (weight 68.0)Pfizer (weight 68.0)United States (weight 7.0)European Union (weight 5.0)Anthropic (weight 4.0)Texas (weight 3.0)China (weight 3.0)Senator (weight 2.0) MerckPfizerUnited StatesEuropean UnionAnthropicTexasChinaSenator Novartis (degree 8) Novartis
Centrality History
2026-04-25 2026-05-25 10 0 Degree Mentions
EntityWeight StatusFirst Seen
Merck 68 STRENGTHENED
Pfizer 68 STRENGTHENED
United States 7 STABLE
European Union 5 STABLE
Anthropic 4 NEW
Texas 3 STABLE
China 3 STABLE
Senator 2 NEW
DOD 2 STABLE
CEO 2 STABLE
AstraZeneca 2 NEW
Airbus 2 NEW
Asia 2 NEW
Barclays 2 NEW
Ohio 1 NEW
Massachusetts 1 NEW
Article Coverage (0)
DateLaneTitle
No Plocamium-authored coverage yet. This entity surfaces in upstream signals (news, filings, trials) but has not yet been a primary subject of a published article. Watch this entity to be alerted when one is published.

Request Access

Full PSI intelligence, network analysis, EDGAR filings, and predicted links require an access token.

Data as of 2026-05-25 ← Intelligence Network